Rothschild-Gronau C, Borchert P, Radukic MT, Haverkamp L, Coras R, Simon M, Müller KM (2026)
Publication Type: Journal article
Publication year: 2026
Book Volume: 16
Article Number: 24908
Journal Issue: 1
DOI: 10.1038/s41598-026-62481-8
Tumor-specific targeting remains a major obstacle for the development of precision cancer therapies. For several tumors and specifically glioblastoma (GBM), an aggressive brain tumor with poor prognosis, more effective treatments are urgently needed. Recombinant adeno-associated viruses (rAAVs), with their established clinical utility and mutational capsid plasticity, offer a promising platform for targeted delivery. We engineered and evaluated modified AAV capsids derived from the established AAV2 with HSPG-tropism knockdown and two less-characterized, tropism-reduced AAV9 variants. The epidermal growth factor receptor (EGFR), a tumor marker often overexpressed in GBM, was targeted by inserting an affibody (Z
APA:
Rothschild-Gronau, C., Borchert, P., Radukic, M.T., Haverkamp, L., Coras, R., Simon, M., & Müller, K.M. (2026). Shifting AAV9 tropism by binding moiety insertion enhances transduction of tumor cell lines and human glioblastoma explants. Scientific Reports, 16(1). https://doi.org/10.1038/s41598-026-62481-8
MLA:
Rothschild-Gronau, Claire, et al. "Shifting AAV9 tropism by binding moiety insertion enhances transduction of tumor cell lines and human glioblastoma explants." Scientific Reports 16.1 (2026).
BibTeX: Download